All In Biotech

Drug Trial Radar · NCT07190482

Treatment of Tinnitus With Olanzapine

Treatment of Tinnitus With Olanzapine: A Randomized Crossover Versus Placebo Study

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Oct 1, 2023

Primary completion

Dec 20, 2024

Study completion Jan 20, 2025

Sponsor

Lead sponsor
University of Sao PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research aims to evaluate the effects of the drug olanzapine on the discomfort caused by tinnitus according to each patient's personality traits. Olanzapine is a drug used as an antipsychotic whose mechanism of action makes it potentially useful for the treatment of tinnitus.

Conditions

  • Tinnitus
  • Tinnitus, Subjective

Interventions

  • Olanzapine 5 Mg ORAL TABLETDrug

    OLANZAPINE ARM

  • Placebo DrugDrug

    placebo administered for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of olanzapine in reducing tinnitus symptoms in a randomized placebo-controlled crossover trialTime frame: From enrollment to the end of treatment at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Ethics Committee (CEP)

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.